anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled. Tumor response and disease progression were evaluated according to RECIST 1.1 criteria, and safety was assessed per CTCAE-5.0 standards.
Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
Blastocystis spp. are the most common intestinal protozoan parasites detected in human stool samples. While identified long before today, its pathogenicity remains controversial. It is generally asymptomatic but in symptomatic cases, many gastrointestinal symptoms, especially diarrhea, have been associated with Blastocystis infection. In recent years, the relationship between the symptoms observed in cases and Blastocystis subtypes (ST) has been reported. The aim of this study was to detect Blastocystis in diarrheal cases admitted to the Aydın Adnan Menderes University Faculty of Medicine, Department of Parasitology Laboratory, to determine subtypes and allele diversity and to investigate its relationship with clinical symptoms. For this purpose, diarrheal stool samples of 200 cases were included in the study and their demographic characteristics (age, gender, residence) and clinical findings (abdominal pain, dyspepsia, nausea-vomiting, weakness, weight loss, anal itching, rash, urticaria) were recorded. Blastocystis was detected by direct microscope method (DM) and by molecular analyses which were performed with polymerase chain reaction (PCR). Subtype diversity was determined based on DNA sequence analysis by PCR targeting the Blastocystis ribosomal ribonucleic acid small subunit (SSU rRNA) gene. In addition, alleles related to Blastocystis subtypes were determined and statistically compared between all data and clinical findings. In the current study, Blastocystis was detected in 31 (15.5%) samples by DM and in 35 (17.5%) samples by PCR specific to the Blastocystis SSU rRNA gene among 200 diarrheal stool samples. No statistical difference was detected between Blastocystis and demographic characteristics. Dyspepsia and nausea-vomiting symptoms differed significantly in cases with Blastocystis compared to negative ones (p= 0.0025, p= 0.0498). Blastocystis subtype was detected in 33 samples by SSU rRNA sequence analysis, and the subtype distribution was ST1 (n= 10, 30.3%), ST2 (n= 4, 12.1%) and ST3 (n= 19, 57.6%). In the statistical evaluation between clinical findings and Blastocystis subtypes, a relationship was found between dyspepsia and Blastocystis ST3 (p= 0.0039). The allele diversity of Blastocystis subtypes was determined as allele 4 (10/10) in all ST1, allele 11 (2/4) and 12 (2/4) in ST2, allele 34 (14/19), 36 (4/19), and 38 (1/19) in ST3. In conclusion, our study provides important data on the molecular epidemiological characteristics of the Blastocystis by determining positivity, subtypes and alleles in diarrheal cases. Therefore, within the scope of the one health approach, comprehensive molecular epidemiological studies are required to determine the presence and genotypes of Blastocystis in human, animal and environmental samples.
PURPOSE:To provide an antithrombin agent prepared by adding a solvent, a diluent and an emulsifier to an arginine amide, improved in local absorption and useful as eye drops, etc. CONSTITUTION:An antithrombin agent prepared by dissolving an N<2>-alkyl-2- carboxypiperidino; R<2> is phenyl or a condensed polycyclic compound residue such as 2-methyl-1,2,3,4-tetrahydro-8-quinolinyl] or its salt in a solvent, adding a diluent for dilution and admixing an emulsifier for emulsification. As the solvent, an unsaturated fatty acid or a water/ethanol mixture solvent is preferably used. As the diluent, a vegetable oil or a hydrocarbon is preferably used. This antithrombin agent is a preventive for formation of thrombus or fibrin, a thrombolytic agent or a medicine for maintaining or improving local blood circulation and useful especially as eye drops. The dosage form may be an oral medicine or a parenteral medicine.
The invention discloses traditional Chinese medicine double-effect cosmetic powder for removing beverage and acne. The traditional Chinese medicine double-effect cosmetic powder is prepared from the raw materials in parts by weight: 10-15 parts of radices lithospermi, 20-35 parts of angelica sinensis, 10-20 parts of ligusticum wallichii, 25-30 parts of radix ampelopsis, 45-50 parts of Japanese ardisia herb, 8-10 parts of radix paeoniae alba, 10-20 parts of prepared rehmannia root, 10-20 parts of radix bupleuri, 15-20 parts of lucid ganoderma, 8-12 parts of flowers carthami, 6-8 parts of Chinese yam, 20-30 parts of fruit of Chinese wolfberry, 8-14 parts of tuckahoe, 3-5 parts of almond, 4-8 parts of loofah sponge, 10-15 parts of liquorice, 10-20 parts of radix rehmanniae recen, 8-10 parts of boxthorn leaf, 25-30 parts of Japanese ardisia herb, 6-10 parts of achyranthes root, 6-10 parts of white atractylodes rhizome, 4-6 parts of moutan bark, and 20-30 parts of semen coicis. The formula is orally taken to replenish qi and nourish blood, nourish liver and kidney, adjust internal secretion, improve irregular menstruation, balance hormone, and improve the immune function. The traditional Chinese medicine double-effect cosmetic powder can be used for adjusting from inside to outside from splash root, preventing oxygen radical from being formed, inhibiting the pigment activity, accelerating degradation of melanin metabolites, and restores normal metabolic function of the skin. The formula is externally used in manners of adjusting the formula in vaseline according to the ratio, evenly coating on the face after cleaning the face by hot water. Therefore, the traditional Chinese medicine double-effect cosmetic powder has the effects of tonifying qi and removing stasis, and scattering evil and promoting circulation of blood.
PURPOSE: The middle cluneal nerve (MCN) is a pure sensory nerve around the middle buttock. Its entrapment between the iliac crest and the long posterior sacroiliac ligament elicits low back pain (LBP) that can be treated by MCN neurolysis or neurectomy. Because few studies examined the pathology of MCN entrapment (MCN-E) we subjected 7 neurectomized specimens from 6 LBP patients to pathologic study.
METHODS: We present 6 consecutive patients (7 sides) with intractable LBP who underwent successful MCN neurectomy. Their symptom duration ranged from 6 to 96 months (average 47.3 months); the follow-up period ranged from 6 to 17 months (average 11.7 months). The surgical outcomes were evaluated using the numerical rating scale (NRS) for LBP and the Roland-Morris Disability Questionnaire (RDQ) score. The resected MCNs underwent neuropathological analysis.
RESULTS: Postoperatively, all 6 patients reported immediate LBP amelioration; their NRS and RDQ scores were improved significantly. Pathological study of the 7 resected nerves showed that the myelinated fiber density was decreased in 6 nerves; we observed marked enlargement (n = 5), perineurial thickening and disruption (n = 6), intrafascicular fibrous changes (n = 5), myelinated fibers separated by fibrous cells under the perineurium (n = 4), and Renaut bodies (n = 3). The 7th nerve appeared normal with respect to the density and size of the myelinated fibers, however, the perineurium was slightly thickened.
CONCLUSION: We present pathological evidence at the MCN compression site of 7 nerves from 6 patients whose LBP was alleviated by MCN neurectomy, indicating that MCN entrapment can elicit LBP.
The invention discloses a composite moisturizing agent characterized in comprising, by weight, 30-50% of glycerol, 15-30% of water, 12-15% of sodium lactate, 12-15% of PCA sodium, 3-10% of allantoin, 2-5% of beta-glucan, 0.5-2.5% of polyquaternium-51, and 0-1% of sodium hyaluronate. The composite moisturizing agent composition provided by the invention has a far better effect against skin water loss than those of independent applications of single components in the composition. The composition provided by the invention has a far better effect for skin elasticity than those of independent applications of single samples. Therefore, the components provide a synergetic effect. When the composition is compounded, skin moisture retention can be improved. Also, the composition provided by the invention has a far better effect in improving skin moisture retention than reference samples such as polyethylene glycol, ceramide, collagen, and chitin. Therefore, the composite moisturizing agent provided by the invention is a high-efficiency moisturizing agent.
The present invention relates to a formula and a preparation thereof of Chinese traditional medicine for curing gastroenteritis and dyspepsia. The formula of Chinese traditional medicine is prepared from 1 to 10 wt. % of amplexicaul jasmine leaf, 1 to 10 wt. % of Chinese knotweed and 1 to 10 wt. % of pomegranate rind. The amplexicaul jasmine leaf, the Chinese knotweed and the pomegranate rind are proportionally mixed, are cut into decoction pieces or are pulverized. A solvent is added for directly extraction for one to three times. An extracting solution is mixed and concentrated. A medicine extract is obtained by drying, and auxiliary materials are added to the extract. A preparation is prepared by a conventional method. By the proof of animal experiments, the medicine which is prepared by using a traditional Chinese medicine formula in the present invention has good curative effect and obvious function. By the indication of acute toxicity tests for mouse, the medicine is safe and has no toxins.
The invention provides a method of reducing the proliferation of a neoplastic cell. The method consists of contacting the neoplastic cell with a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen.  The neoplastic cell specific internalizing antigen can be selected from the group consisting of lamp-2 and limp II families of lysosomal integral membrane proteins. Also provided is a method of intracellular targeting of a cytotoxic or cytostatic agent to a neoplastic cell population. The method consists of administering to an individual containing a neoplastic cell population a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen that is expressed by the neoplastic cell population, wherein the cytotoxic or cytostatic binding agent is bound by the neoplastic cell specific internalizing antigen and is internalized into the intracellular compartment.  A method of reducing tumor growth through the intracellular targeting of a cytotoxic agent is also provided.
Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.

Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)- monoacetate. The structural formula is given below.

Flecainide acetate is a white crystalline substance with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.

Flecainide Acetate Tablets USP also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch and sodium stearyl fumarate.
BACKGROUND: Increased tibial slope has been shown to lead to higher rates of anterior cruciate ligament graft failure. A slope-decreasing osteotomy can reduce in situ anterior cruciate ligament force and may mitigate this risk. However, how this procedure may affect the length change behavior of the medial ligamentous structures is unknown.
PURPOSE/HYPOTHESIS: The purpose of this study was to examine the effect of anterior slope-modifying osteotomies on the medial ligamentous structures. It was hypothesized that (1) decreasing the tibial slope would lead to shortening of the superficial medial collateral ligament (sMCL), (2) while the fibers of the posterior oblique ligament (POL) would be unaffected.
STUDY DESIGN: Descriptive laboratory study.
METHODS: Eight fresh-frozen cadaveric knee specimens underwent anatomic dissection to precisely identify the medial ligamentous structures. The knees were mounted in a custom-made kinematics rig with the quadriceps muscle and iliotibial tract loaded. An anterior slope-modifying osteotomy was performed and fixed using an external fixator, which allowed modification of the wedge height between -15 and +10 mm in 5-mm increments. Threads were mounted between pins positioned at the anterior, middle, and posterior parts of the tibial and femoral attachments of the sMCL and POL. For different tibial slope modifications, length changes between the tibiofemoral pin combinations were recorded using a rotary encoder as the knee was flexed between 0° and 120°.
RESULTS: All sMCL fiber regions shortened with slope reduction (P < .001) and lengthened with slope increase (P < .001), with the anterior sMCL fibers more affected than the posterior sMCL fibers. A 15-mm anterior closing-wedge high tibial osteotomy (ACWHTO) resulted in a 6.9% ± 3.0% decrease in the length of the anterior sMCL fibers compared with a 3.6% ± 2.3% decrease for the posterior sMCL fibers. A 10-mm anterior opening-wedge high tibial osteotomy (AOWHTO) increased anterior sMCL fiber length by 5.9% ± 2.3% and posterior sMCL fiber length by 1.6% ± 1.0%. The POL fibers were not significantly affected by a slope-modifying osteotomy.
CONCLUSION: Tibial slope-modifying osteotomies changed the length change pattern of the sMCL such that an AOWHTO increased whereas an ACWHTO decreased the sMCL strain. This effect was most pronounced for the anterior fibers of the sMCL. The length change pattern of the POL remained unaffected by slope-modifying osteotomy.
CLINICAL RELEVANCE: Surgeons should be aware that anterior tibial slope-modifying osteotomies affect the biomechanics of the sMCL. After an extensive ACWHTO, patients may develop a medial or anteromedial instability, while an AOWHTO may overconstrain the medial compartment.
Awake prone position (APP) for 4 or more hours per day in addition to standard care for the first 72 hours from randomisation. After the initial period, use of APP is at discretion of the treating clinician. Awake prone can be discontinued earlier if patients meets pre-specified criteria of sustained improvement.
Penicillinase-resistant penicillins should generally not be administered to patients with a history of sensitivity to any penicillin.

Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. There is clinical and laboratory evidence of partial cross-allergenicity among penicillins and other β-lactam antibiotics including cephalosporins, cephamycins, and other 1-oxa-β-lactams. Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy.

The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilation, cardiospasm, or intestinal hypermotility. Occasionally patients will not absorb therapeutic amounts of orally administered penicillin.

Prescribing dicloxacillin sodium capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
In the extraction of TC(Trichilia connaroides) by solvent(s), the former is reacted with acidic plant matter such as, for example, amla fruit matter(Emblica officinalis) which converts some of the insoluble principles therein into soluble forms, thus enhancing the extraction range and yield. In extraction by water, the adoption of amla fruit matter increases the TC principles yield from about 10% to about 12% by wt., of the saponins from about 8.2% to about 12.3% by wt. and of the terpenes from about 1.1% to about 3.9% by wt. The corresponding yield figures in extraction by aq. ethanol, respectively with and without the adoption of amla fruit matter are 14%, 15.6% and 5.5% by wt. and 8%, 11.1% and 4.1% by wt. for the three sets of compounds respectively. With both solvents, the adoption of amla increases the yields, said increases being greater in the case of aq. ethanol.
The purpose of this study would be to determine the predictive value of a simple to perform preoperative evaluation in assessing level of anxiety, anticipated pain and the intensity rating of an audio tone to predict level of postoperative pain after surgery.

Study Design: A total of 400 evaluable patients will be studied using the various surgical populations listed. For statistical purposes, the following will be the surgical population by procedure. Two hundred healthy ASA I-II women scheduled for elective cesarean section, one hundred scheduled for elective postpartum tubal ligations, and one hundred scheduled for elective inpatient gynecological surgeries (such as total vaginal hysterectomy, total abdominal hysterectomy) will be consented and enrolled in the study. Normal baseline vital signs will be obtained and recorded as part of usual preoperative assessment for these patients. The patients will be asked about their current level of pain and to rate the intensity of a series of audio tones. At 18-24 hours postoperatively, and again at 36-48 hours postoperatively if applicable, research personnel will evaluate the severity of postoperative pain the patient has at rest and with movement (from supine to sitting upright), using a sliding pain scale from 0 to 100 mm, with 0 being no pain and 100 being the worst pain ever. Information on drug administered in the preoperative, intraoperative and postoperative period will be collected and recorded. The subject can also choose to allow us to follow-up with them in the future to evaluate current residual postoperative pain levels as needed.
PURPOSE:To form a self-adhesive sheet free from a gap at the cuts in the release paper even in long-term storage by laminating a layer of a self-adhesive comprising a styrene/diene/styrene block copolymer on a base sheet made of a specified resin composition. CONSTITUTION:A self-adhesive sheet 4 made by laminating a layer of self-adhesive 2 on a base sheet 1 made of resin and laminating thereon a release paper 3 having cuts 5, wherein the base sheet 1 is made of a resin composition containing 100 pts.wt. base resin (a) comprising a polyurethane/polyvinyl chloride graft copolymer, a polyvinyl chloride polymer or a mixture thereof, 1-20 pts.wt. styrene/ethylene/butylene/styrene block copolymer (b), 1-50 pts.wt. ethylene/vinyl acetate copolymer resin (c), and 10-30 pts.wt. plasticizer comprising a polyester having an average molecular weight of 1,000 or higher and wherein the self-adhesive 2 comprises a styrene/diene/styrene block copolymer.
During the premarketing development of lamotrigine, 20 sudden and unexplained deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-years of exposure). 

Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained death in epilepsy (SUDEP) in patients not receiving lamotrigine (ranging from 0.0005 for the general population of patients with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical development program for lamotrigine, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or suggest concern depends on the comparability of the populations reported upon with the cohort receiving lamotrigine and the accuracy of the estimates provided. Probably most reassuring is the similarity of estimated SUDEP rates in patients receiving lamotrigine tablets and those receiving other AEDs, chemically unrelated to each other, that underwent clinical testing in similar populations. Importantly, that drug is chemically unrelated to lamotrigine. This evidence suggests, although it certainly does not prove, that the high SUDEP rates reflect population rates, not a drug effect.
Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive ribociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
The present invention relates to a derivative of alkaline substances, such as arginine of sulfalene oxazole, etc., or alkali. The present invention basically contains alkaline substances, such as sulfalene oxazole, arginine, etc., or alkali. The present invention provides a preparation method of the derivative of alkaline substances, such as arginine of sulfalene oxazole, etc., or alkali. The alkaline substance, such as sulfalene oxazole, arginine, etc., or the alkali is dissolved in ethanol, the ethanol is volatilized, and through porphyrization, the derivative of alkaline substances, such as arginine of sulfalene oxazole, etc., or alkali is obtained. A solid preparation or a liquid preparation can be prepared, or the alkaline substance, such as sulfalene oxazole, arginine, etc., or the alkali is dissolved in water or other kinds of solvent to be prepared into the liquid preparation. The derivative of the present invention can be singly prepared into a compound preparation or can be matched with other kinds of medicine to be prepared into a compound preparation, and the compound preparation is used for being prepared into solid or liquid preparations, such as oral preparations, injection preparations, percutaneous absorption preparations, eye drops, suppository, spraying agents, nose drops, etc. The present invention has the advantages of simple technology and low cost. The requirement of industrial preparation can be satisfied.